The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Lundbeck and Innovative Pharma have joined the Federation, thus bringing its membership up to 28 leading international companies and 45 national and regional industry associations.
Lundbeck is a global pharmaceutical company conducting research for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy and insomnia.
According to the World Health Organization, WHO, more than 700 million cases of brain disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. IFPMA Director General Eduardo Pisani said: “With one in three people suffering from mental disorders at some point during their life, diagnoses and discrimination of mental illness puts a major strain on societies and economies as poor mental health has a direct impact on people’s ability to work. In addition, there is increasing evidence for links between diseases such as diabetes and mental health. This underlines the need for joined up thinking when trying to tackle these issues at a policy level.”
The Association “Innovative PHARMA” (InPharma) is a non-profit organization of global research- based pharmaceutical companies operating in Russia. Its members are Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Merck Sharp&Dohme, Novartis Pharma, Novo Nordisk and Pfizer. InPharma has a keen interest to provide the perspective of its members operating in Russia on global policy issues that foster biopharmaceutical innovation, and that address quality standards of medicines as well as ethical business practices.
Geneva, 23 June 2011
